-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Downgrades Evolent Health to Neutral, Raises Price Target to $6.75

Benzinga·07/23/2026 11:25:06
Listen to the news
Citigroup analyst Daniel Grosslight downgrades Evolent Health (NYSE:EVH) from Buy to Neutral and raises the price target from $5.5 to $6.75.